Has Rao Pasupuleti, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,501 in general payments to Rao Pasupuleti, MD across 701 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rao Pasupuleti, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rao Pasupuleti, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rao Pasupuleti, MD

Neurology with Special Qualifications in Child Neurology · Hamilton, NJNPI 1891893541

Payments from drug & device makers

$10,501in general payments, 2019–2025

Across 701 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Supernus Pharmaceuticals, Inc.$971
AbbVie$913
Biogen$815
EMD Serono, Inc.$660
Corium, LLC$641
UCB, Inc.$571
plus $6K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Supernus Pharmaceuticals, Inc.	60	$971
AbbVie(2 entities)	68	$913
Biogen	53	$815
EMD Serono, Inc.	48	$660
Corium, LLC	51	$641
UCB, Inc.	36	$571
Novartis	27	$557
Tris Pharma Inc	36	$514
Sunovion Pharmaceuticals Inc.	21	$330
Takeda Pharmaceuticals U.S.A., Inc.	24	$329
Eisai Inc.	19	$267
Teva Pharmaceuticals USA, Inc.	17	$223
Neos Therapeutics, LP	14	$189
Neurelis, Inc.	13	$183
Ironshore Pharmaceuticals Inc.	13	$182
SK Life Science, Inc.	10	$181
Jazz Pharmaceuticals Inc.	12	$179
Lilly USA, LLC	12	$179
Bristol Myers Squibb	12	$173
Sumitomo Pharma America, Inc.	9	$154
Biohaven Pharmaceuticals, Inc.	13	$152
Neurocrine Biosciences, Inc.	10	$149
Aquestive Therapeutics, Inc.	9	$145
Aprecia Pharmaceuticals, LLC	9	$141
AstraZeneca	10	$138
Amgen(2 entities)	9	$126
Greenwich Biosciences, Inc.	3	$108
Impel Pharmaceuticals Inc.	5	$84
Avanir Pharmaceuticals, Inc.	6	$82
Boston Scientific	4	$80
Biohaven Pharmaceutical Holding Company Ltd.	5	$77
Argenx US, Inc.	4	$67
Medtronic(2 entities)	3	$59
Livanova USA, Inc.	1	$58
Mallinckrodt Hospital Products Inc.	4	$55
Mallinckrodt Enterprises LLC	4	$54
Amneal Pharmaceuticals LLC	4	$51
Arbor Pharmaceuticals, Inc.	3	$45
Abbott	2	$42
Shire North American Group Inc	3	$41
Axsome Therapeutics, Inc.	2	$37
Acorda Therapeutics, Inc	3	$35
Upsher-smith Laboratories LLC	2	$33
Strongbridge US Inc.	2	$30
Johnson & Johnson	2	$29
Adamas Pharmaceuticals, Inc.	2	$29
Rhodes Pharmaceuticals L.p.	2	$26
Kyowa Kirin, Inc.	2	$25
Biomarin Pharmaceutical Inc.	1	$22
Springworks Therapeutics, Inc.	1	$20
ANI Pharmaceuticals, Inc.	1	$20
Pfizer	1	$19
Azurity Pharmaceuticals, Inc.	1	$18
Otsuka America Pharmaceutical, Inc.	1	$17
Bausch Health US, LLC	1	$17
Noven Therapeutics, LLC	1	$16
Adlon Therapeutics L.p.	1	$15
Cycle Pharmaceuticals Inc	1	$15
Vertical Pharmaceuticals, LLC	1	$15
Kowa Pharmaceuticals America, Inc.	1	$15

How this compares

$10,501 in reported general payments places this provider in the 80th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.

See all neurology with special qualifications in child neurology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$127,226

Medicare patients

384

Services billed

1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Hamilton

Vikram BhiseNew Brunswick$593K
Carlos LastraNew Brunswick$502K
Mark MintzVoorhees$322K
Ignacio ValenciaCamden$256K
Rajeshwari MahalinghamNew Brunswick$242K
Shannon BabineauMorristown$240K
Juliann PaolicchiHackensack$180K
Amanda SpinnerNew Brunswick$51K
Matthew McCarthyFlorham Park$30K
Romana KulikovaGarwood$28K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →